Bayer HealthCare and Regeneron Announce Regulatory Submission of EYLEA® (aflibercept) Injection for the Treatment of Diabetic Macular Edema in Japan

Bayer HealthCare and Regeneron Announce Regulatory Submission of EYLEA® (aflibercept) Injection for the Treatment of Diabetic Macular Edema in Japan

[at noodls] – TARRYTOWN, N.Y., March 3, 2014 /PRNewswire/ — Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that Bayer HealthCare’s Japanese subsidiary, Bayer Yakuhin, Ltd., has submitted an application … more

View todays social media effects on REGN

View the latest stocks trending across Twitter. Click to view dashboard

See who Regeneron is hiring next, click here to view

Share this post

Comments (0)